Maze Therapeutics, Inc. (MAZE)
MAZENASDAQ-GMBiotechnology: Biological Products (No Diagnostic Substances)
$35.45
+0.5400 (+1.55%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $1.97bn
- P/E
- –
- EPS, last 4 quarters
- $-2.65
- Dividend yield
- –
- Day range
- –
- 52-week range
- $21.95 to $53.65
- Average volume
- 748.4k
- Previous close
- $34.91
Analysts
9 coveringBuy9 buy, 0 hold, 0 sell
Targets a year out average $61.67, +74.0% from here
Earnings
next estimate $-0.8000Next report
Dec 2025
+11.0%
Mar 2026
-4.7%
Jun 2026
0.0%
Sep 2026
-1.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | $20.00m | – |
| Gross profit | – | – | $20.00m | – |
| Operating income | -$32.97m | -$38.06m | -$26.55m | -$48.03m |
| Net income | -$30.09m | -$34.57m | -$24.21m | -$44.73m |
News
8 latest- Wall Street Analysts Predict a 93.92% Upside in Maze Therapeutics, Inc. (MAZE): Here's What You Should KnowZacks · 7 days ago
- What Makes Maze Therapeutics, Inc. (MAZE) a New Buy StockZacks · Oct 19, 2026
- How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%Zacks · Oct 19, 2026
- 3 Small-Cap Stocks With Catalysts That Could Put Them in the SpotlightMarketBeat · Oct 5, 2026
- Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000The Motley Fool · Sep 11, 2026
- Maze Posts Wider Loss In Q2; Expects Phase 2 CIPheR Data For MZE782 In FY27 RTTNews · Aug 12, 2026
- Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?Zacks · Jul 21, 2026
- What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?The Motley Fool · Jun 29, 2026
The company
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze's pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor in Phase 2 development with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- mazetx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.